Acura Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2021
May 17, 2021 at 04:15 pm
Share
Acura Pharmaceuticals, Inc. announced unaudited consolidated financial results for the first quarter ended March 31, 2021. For the quarter, the company reported total revenues of $644,000 against $1.091 million a year ago. Operating loss was $146,000 against $483,000 a year ago. Net loss was $243,000 against $595,000 a year ago. Net loss per basic and diluted share was $0.01 against $0.02 a year ago.
Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
ACURA PHARMACEUTICALS, INC. 
